

## ABL Bio, WuXi Bio expand strategic collaboration for \$220M

26 February 2019 | News

**WuXi Biologics will receive an upfront payment as well as development, regulatory and commercial milestone payments of about \$220 million, and will be entitled to royalties based on global sales of these programs**



WuXi Biologics a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and ABL Bio Corporation South Korean Biotechnology Company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases have announced the expansion of their strategic partnership for novel bispecific antibodies and immune-oncology program.

Under the terms of the agreements, ABL Bio has rights to use WuXi Biologics' proprietary discovery platforms, including WuXiBody™ and CD3 platform, to research, develop and commercialize multiple bispecific antibodies, as well as rights to develop new bispecific antibodies targeting novel immune check point receptor. WuXi Biologics will receive an upfront payment as well as development, regulatory and commercial milestone payments of about \$220 million, and will be entitled to royalties based on global sales of these programs.

In November 2018, ABL Bio and WuXi Biologics announced an exclusive development and clinical manufacturing partnership for multiple bispecific antibodies. This announcement further strengthens the breadth and depth of the companies' collaboration.